Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant SADBE for Congenital Melanocytic Nevi
NCT04999631Phase 1Not yet recruiting
- Sponsor
- Massachusetts General Hospital
- Start
- Jan 2027
- Primary completion
- Jan 2030
- Modality
- Small Molecules
01
Overview
Phase 1, randomised trial of squaric acid dibutyl ester in Congenital melanocytic nevus (CMN) (2 arms), sponsored by Massachusetts General Hospital. Primary endpoint: Number of melanocytes per mm2 at 12 weeks. Planned start Jan 2027; status: not yet recruiting.
02
Drugs
squaric acid dibutyl ester
03
Conditions
Congenital melanocytic nevus (CMN)
Beyond the preview
Go deeper on NCT04999631.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04999631.